<DOC>
	<DOCNO>NCT00066651</DOCNO>
	<brief_summary>RATIONALE : Immunotoxins locate tumor cell kill without harm normal cell . Immunotoxin therapy may effective treat advanced solid tumor . PURPOSE : This phase I trial study side effect best dose immunotoxin therapy treat patient recurrent unresectable advanced solid tumor .</brief_summary>
	<brief_title>Immunotoxin Therapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose SS1 ( dsFv ) -PE38 immunotoxin patient advance mesothelin-expressing malignancy . Secondary - Determine toxic effect drug patient . - Determine plasma pharmacokinetics drug patient . - Determine response patient treated drug . - Correlate induction antibody drug pharmacokinetics patient . OUTLINE : This open-label , dose-escalation study . Patients receive test dose SS1 ( dsFv ) -PE38 immunotoxin IV 1-2 minute day 1 follow SS1 ( dsFv ) -PE38 immunotoxin IV 30 minute day 1 , 3 , 5 . Treatment repeat every 4 week 3 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SS1 ( dsFv ) -PE38 immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-15 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced malignancy 1 follow type : Ovarian cancer All nonmucinous epithelial histology eligible Primary peritoneal cavity cancer Fallopian tube cancer Malignant mesothelioma No sarcomatous histology Pancreatic cancer Squamous cell cancer ( SCC ) lung SCC cervix SCC head neck Recurrent unresectable disease , meet 1 follow criterion : Previously treat definitive standard therapy Patient refuse prior standard therapy Initial recurrent tumor positive ( least 30 % tumor cell ) mesothelin immunohistochemistry* NOTE : *Immunohistochemical evaluation require patient pancreatic cancer Measurable evaluable disease No clinically significant pericardial effusion No known CNS spinal cord involvement tumor PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 75,000/mm^3 Hepatic Bilirubin great upper limit normal ( ULN ) AST ALT great 2.5 time ULN Albumin least 3.0 g/dL Hepatitis B C negative Seropositive allow clinically asymptomatic except clinically asymptomatic bilirubin AST ALT meet outline criterion Renal Creatinine great ULN Calcium great ULN Cardiovascular No New York Heart Association class IIIV cardiovascular disease Pulmonary Oxygen saturation least 93 % room air DLCO least 50 % predicted* Total lung capacity vital capacity least 50 % predicted* FEV_1 least 50 % predicted* NOTE : *For patient pleural mesothelioma clinically indicate Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No infection require parenteral antibiotic No HIV infection Serum neutralizing activity SS1 ( dsFv ) PE38 immunotoxin ( 200 ng/mL ) great 75 % PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 4 week since prior therapy recover No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>ovarian carcinosarcoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>Brenner tumor</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
</DOC>